Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Your Complete Guide to Cataract Surgery
Cataract surgery is a safe, effective procedure that improves vision by removing cloudy lenses from the eyes and replacing them with artificial lenses. As technology advances and techniques improve, understanding the nuances of cataract surgery is crucial for anyone considering…
CAM360 AmnioGraft: BioTissue’s Ocular Surface Therapy
BioTissue announced the launch of CAM360 AmnioGraft (CAM360 AG), a new, hydrated, shelf-stable ‘Cryopreserved Amniotic Membrane’ (CAM) solution designed for treating dry eye and various ocular surface disorders. Initial shipments of the product have commenced, with nationwide availability expected by…
Melt Pharmaceuticals Launches MELT-300 Phase 3 Program
Melt Pharmaceuticals has completed the dosing of its first patient in its phase 3 program for MELT-300, marking a crucial step in evaluating the safety and efficacy of this pioneering product. MELT-300 is a non-intravenous, non-opioid tablet comprising fixed doses…
Rayner Announces 3 Key Appointments to Management Board
Rayner has made three key additions to its management board to foster continued growth and development within the organization. James Crutchlow has been appointed as Chief Commercial Officer, Rob Nadler as Chief Growth Officer, and Chris Willis as Chief Marketing…
Harrow Reveals 52-Week Data for Vevye ESSENCE-2 Study
Harrow, a leading pharmaceutical company, has revealed the encouraging results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, a novel treatment for dry eye disease (DED). Study Design and Outcomes: ESSENCE-2 OLE Analysis The…
Italy Probes Pharma Giants for Market Manipulation
Italy’s antitrust regulator has initiated a probe into several pharmaceutical giants, including Novartis, amid suspicions of anti-competitive practices in the sale of a drug targeting eye conditions. The investigation follows concerns regarding potential market restrictions and delayed product launch of…
Eversight Partners with LighTopTech to Improve Eye Imaging
Eversight has partnered up with LighTopTech to elevate the standards of imaging modalities for eye tissues. This ambitious partnership, spanning over four years, sets out to redefine the landscape of ocular imaging in both clinical and research domains. LighTopTech’s OCX…
CorneaGen Launches CTAK for Keratoconus Patients
CorneaGen, a leading provider of ocular tissue, announced the commercial launch of Corneal Tissue Addition for Keratoplasty (CTAK), a novel solution for corneal contouring in keratoconic eyes. Developed in collaboration with CTAK LLC and Ziemer, CTAK offers patient-ready, gamma-irradiated sterile…
BIOPHTA Secures €6.5M to Advance Eye Disease Therapy
BIOPHTA, a preclinical biotech company, has successfully closed a Seed round, raising €6.5 million to advance its pioneering technology into clinical development for the treatment of glaucoma and macular edema. This significant funding injection, led by prominent European venture capital…
Phase 3 Trial for AZR-MD-001 in MGD Patients Begins
Azura Ophthalmics has reached a significant milestone with the enrollment of the first patient in the ASTRO study—a phase 3 clinical trial evaluating the efficacy and safety of AZR-MD-001 in patients grappling with clinical signs and symptoms of meibomian gland…